Immunocore
IMCR
IMCR
109 hedge funds and large institutions have $1.61B invested in Immunocore in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1.2% more ownership
Funds ownership: 66.78% → 67.98% (+1.2%)
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
6% less capital invested
Capital invested by funds: $1.73B → $1.61B (-$112M)
Holders
109
Holding in Top 10
9
Calls
$22.8M
Puts
$3.27M
Top Buyers
| 1 | +$60.4M | |
| 2 | +$21.8M | |
| 3 | +$21.1M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$13.4M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$13.3M |
Top Sellers
| 1 | -$19M | |
| 2 | -$15.8M | |
| 3 | -$10.9M | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$10.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.89M |